Jason Hoitt, Chief Patient Officer at Stoke Therapeutics, Inc. (STOK), sold 7,394 shares at $32.74 ($238K) on 2026-03-17, disclosed to the SEC on 2026-03-19.
Open-market sale of $238k STOK by Chief Patient Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.74 | 1,033 | $34K | 14.2% |
| 2 | $32.74 | 1,033 | $34K | 14.2% |
| 3 | $33.38 | 748 | $25K | 10.5% |
| 4 | $33.38 | 748 | $25K | 10.5% |
| 5 | $31.28 | 1,762 | $55K | 23.2% |
| 6 | $31.28 | 1,762 |
| $55K |
| 23.2% |
| 7 | $31.79 | 139 | $4K | 1.9% |
| 8 | $31.79 | 139 | $4K | 1.9% |
| 9 | $32.85 | 30 | $986 | 0.4% |
| Total | $32.14 avg | 7,394 | $238K | 100% |
| Filing → |
| DOVA | SELL | 2019-10-02 | $67K | — | Filing → |
| DOVA | SELL | 2019-07-16 | $116K | — | Filing → |
| DOVA | SELL | 2019-07-02 | $33K | — | Filing → |